Prognostic factors and combined use of tocilizumab and corticosteroids in a Spanish cohort of elderly COVID-19 patients.
J Med Virol
; 94(4): 1540-1549, 2022 04.
Article
em En
| MEDLINE
| ID: mdl-34845754
ABSTRACT
Coronavirus disease 2019 (COVID-19) infection in elderly patients is more aggressive and treatments have shown limited efficacy. Our objective is to describe the clinical course and to analyze the prognostic factors associated with a higher risk of mortality of a cohort of patients older than 80 years. In addition, we assess the efficacy of immunosuppressive treatments in this population. We analyzed the data from 163 patients older than 80 years admitted to our institution for COVID-19, during March and April 2020. A Lasso regression model and subsequent multivariate Cox regression were performed to select variables predictive of death. We evaluated the efficacy of immunomodulatory therapy in three cohorts using adjusted survival analysis. The mortality rate was 43%. The mean age was 85.2 years. The disease was considered severe in 76.1% of the cases. Lasso regression and multivariate Cox regression indicated that factors correlated with hospital mortality were age (hazard ratio [HR] 1.12, 95% confidence interval [CI] 1.03-1.22), alcohol consumption (HR 3.15, 95% CI 1.27-7.84), CRP > 10 mg/dL (HR 2.67, 95% CI 1.36-5.24), and oxygen support with Venturi Mask (HR 6.37, 95% CI 2.18-18.62) or reservoir (HR 7.87, 95% CI 3.37-18.38). Previous treatment with antiplatelets was the only protective factor (HR 0.47, 95% CI 0.23-0.96). In the adjusted treatment efficacy analysis, we found benefit in the combined use of tocilizumab (TCZ) and corticosteroids (CS) (HR 0.09, 95% CI 0.01-0.74) compared to standard treatment, with no benefit of CS alone (HR 0.95, 95% CI 0.53-1.71). Hospitalized elderly patients suffer from a severe and often fatal form of COVID-19 disease. In this regard, several parameters might identify high-risk patients upon admission. Combined use of TCZ and CS could improve survival.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Corticosteroides
/
Anticorpos Monoclonais Humanizados
/
COVID-19
/
Tratamento Farmacológico da COVID-19
Tipo de estudo:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Aged80
/
Female
/
Humans
/
Male
País/Região como assunto:
Europa
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article